NDAORALTABLET
Approved
Jun 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
STALEVO 75 (carbidopa, levodopa, and entacapone) by Orion Pharma is catechol o-methyltransferase inhibitors [moa]. Approved for catechol-o-methyltransferase inhibitor [epc]. First approved in 2003.
Drug data last refreshed 7h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STALEVO 75 is an oral tablet combining carbidopa, levodopa, and entacapone for Parkinson's disease management. It works by inhibiting DOPA decarboxylase and catechol-O-methyltransferase to increase dopamine availability in the brain. This triple-combination formulation extends levodopa half-life and reduces motor fluctuations in advanced Parkinson's patients.
$0.018BPart D
LOE ApproachingDeclining
As a niche Parkinson's product approaching loss of exclusivity with minimal spending ($18K in 2023), the brand team is likely small and focused on maximizing remaining franchise value before generic erosion.
Mechanism of Action
Catechol O-Methyltransferase Inhibitors
Pharmacologic Class:
Catechol-O-Methyltransferase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Levodopa Concentration Profile With Stalevo 75/125 mg
Started Dec 2009
20 enrolled
Parkinson's Disease
Career Relevance
Working on STALEVO 75 offers limited career growth due to minimal linked job openings (0) and approaching loss of exclusivity. Roles are primarily defensive, focused on protecting existing market share and managing generic transition rather than driving innovation or expansion.
Brand Manager
Worked on STALEVO 75 at Orion Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.